PAYS screens as a small-cap MOMENTUM candidate: Q2 2026 EPS beat consensus by roughly 83%, revenue grew 48%, adjusted EBITDA grew 113%, guidance was raised, and the stock is trading close to its 52-week high. The due diligence is deliberately stricter than the screen: the business quality is improving fast, but a 37x forward P/E and 20x forward EBITDA leave only measured base-case upside.
Factor weights follow MOMENTUM mode: 35% bull / 40% base / 25% bear. The factor changes scenario weights, not the valuation multiple. Base FV is close to public targets, so the report's conclusion is favorable but not aggressive. Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| FY2026 EBITDA enterprise value | $36.5M FY2026E adj. EBITDA midpoint x 21.0x EV/EBITDA / 56.46M shares | +13.58 |
| Net cash / debt bridge | ($27.37M cash - $5.71M debt) / 56.46M shares | +0.38 |
| Growth option value | 25% probability x $120M value for pharma programs compounding beyond FY2026 / 56.46M shares | +0.53 |
| Dilution reserve | -5.0% dilution haircut x $13.42 current price due to +10.93% YoY shares | -0.67 |
| Regulatory/customer concentration reserve | -$18.9M reserve for copay-rule and program-concentration risk / 56.46M shares | -0.33 |
| FCF conversion credit | 10% probability x $71M TTM FCF-quality upside / 56.46M shares | +1.26 |
| FV base case | Explicit sum of components above | $14.75 |
Insider check: recent Form 4 aggregators show CEO Mark Newcomer sold about $1.78M on Aug 7, 2026 and Joan Herman sold more than $500K on Jul 16 and Jun 30, 2026. Litigation/governance searches did not surface an active PAYS securities class action, short-seller report, SEC investigation or going-concern warning in the last 12 months.
| Item | FY2023 | FY2024 | FY2025 | FY2026E | Guidance / note |
|---|---|---|---|---|---|
| Total revenue | ~$47.4M | ~$58.5M | $82.0M | $114-$117M | Q2 2026 guide raised |
| Net income | $6.46M | $3.82M | $7.55M | $21.5-$23.0M | FY2026 guide after Q2 raise |
| Adjusted EBITDA | $6.71M | $9.62M | $19.94M | $35-$38M | Midpoint +83% vs FY2025 |
| Diluted EPS | $0.12 | $0.07 | $0.13 | $0.35-$0.37 | Guidance materially above pre-Q2 consensus |
| Cash / debt | N/D | N/D | $21.1M / $6.0M | $27.4M / $5.7M | Q2 2026 balance sheet |
| Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 19.08 | 21.60 | 22.80 | 28.04 | 28.25 |
| Gross margin % | 61.6% | N/D | N/D | N/D | 63.3% |
| Net income ($M) | 1.39 | N/D | N/D | 5.44 | 6.76 |
| Cash EOP ($M) | N/D | N/D | 21.1 | N/D | 27.37 |
Business model - healthcare payments with operating leverage
Pharma patient affordability $30.33M H1 2026, +85.2% YoY ramping Largest growth engine; 148 active programs at Q2 exit after 51 net additions over 12 months. Plasma donor payments $24.79M H1 2026, +23.0% YoY stable Mature payment rail with 561 centers at Q2 exit; still important, but no longer the sole thesis. Other / platform services $1.17M H1 2026, +2.0% YoY small Small residual category; value comes from platform extensibility rather than current revenue size.
Legal, regulatory and risk analysis
SWOT analysis
- +Revenue growth near 50% with gross margin above 63%.
- +Patient affordability gives PAYS a higher-growth second engine beyond plasma.
- +Net-cash balance sheet and strong cash conversion.
- −The stock already prices in a lot of execution success.
- −Share dilution is running faster than ideal for a profitable small cap.
- −Short-interest data was not reliably found in free sources.
- →More pharma program launches can keep FY2027 growth above mature processor peers.
- →Operating leverage can move EBITDA margin higher if SG&A scales slowly.
- →A clean Q3 print can pull analyst targets above the current $15 area.
- !Copay-rule changes or pharma budget tightening can slow the strongest segment.
- !A single weak guide could compress the premium multiple quickly.
- !Continued insider selling can cap sentiment after the rerating.
Summary by assessment area
- Q2 beat, guidance raise and near-high price action justify the factor screen.
- Growth is fundamental, not just multiple expansion.
- Base FV is only about 10% above the analysis price.
- The stock needs FY2027 growth visibility for a higher target.
- Track Q3 revenue, program count, dilution and insider sales.
- Regulatory risk is the main non-financial variable.
Sources: Paysign Q2 2026 earnings release filed Aug 5, 2026; Paysign Q2 2026 Form 10-Q; Paysign Q2 2026 transcript; Paysign FY2025 results release and 2025 10-K; StockAnalysis PAYS statistics and valuation; Investing.com PAYS earnings page; Webull PAYS quote snapshot; Yahoo Finance PAYS quote snippet; PriceTargets/Barrington Research target snippet; InsiderFlow and Levi & Korsinsky insider transaction snippets; peer valuation snippets from StockAnalysis, Yahoo Finance, MarketScreener and FinanceCharts. Market data - last verified analysis price Sep 30, 2026: PAYS ~$13.42, market cap ~$757.7M, 52W range $3.08-$14.43, 56.46M shares outstanding. Short interest: N/D from reliable free dated source. This document is for informational purposes only and does not constitute financial or investment advice.